GSK plc stock (GB0009252882): Annual Report 2025 published

GSK plc has released its Annual Financial Report for the year ended December 31, 2025, available on the company website and filed with regulators. The London-based pharma giant focuses on vaccines and specialty medicines amid US market exposure.

GSK plc released its Annual Financial Report for the year ended December 31, 2025, publishing it on the GSK Group website and submitting it to the UK's Financial Conduct Authority National Storage Mechanism, Investegate as of recent. This follows the company's global operations in pharmaceuticals, vaccines, and specialty treatments, with shares listed on NYSE for US investors.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GSK plc
• Sector/industry: Medical / Pharmaceuticals
• Headquarters/country: London, UK
• Core markets: Global, including US
• Key revenue drivers: Vaccines, specialty medicines
• Home exchange/listing venue: NYSE (GSK), LSE
• Trading currency: USD (NYSE), GBP (LSE)

GSK plc: core business model

GSK plc develops, manufactures, and commercializes prescription medicines, vaccines, and specialty treatments worldwide. Headquartered in London, the company resulted from the 2000 merger of Glaxo Wellcome and SmithKline Beecham, MarketBeat overview. It employs over 66,000 people and maintains a dual listing on the London Stock Exchange and NYSE, providing direct access for US retail investors.

The business emphasizes immunology, respiratory, and infectious diseases, with vaccines forming a key pillar. GSK's portfolio includes blockbuster products like Shingrix for shingles prevention, which has driven significant revenue growth in recent years.

Main revenue and product drivers for GSK plc

Vaccines represent a primary revenue driver, contributing substantially to sales. Specialty medicines in HIV, oncology, and respiratory areas also fuel growth. For the year ended December 31, 2025, detailed financials are outlined in the newly published annual report, Investegate as of publication.

GSK's NYSE shares traded with a market capitalization of $103.38 billion, P/E ratio of 13.24, and dividend yield of 3.69% as reported in recent data, MarketBeat as of recent. This positions it as a dividend-focused option in the US-listed pharma space.

Industry trends and competitive position

The pharmaceutical sector sees rising demand for vaccines and biologics, areas where GSK holds strong positions against peers like Johnson & Johnson. GSK's EBITDA stood at $8.61 billion per comparative data published with year-to-date figures, highlighting operational scale, Tickeron comparison.

Recent news includes FDA-related developments on autism treatments, though not directly tied to GSK products, reflecting broader sector scrutiny as of October 31, 2025, Marketscreener as of 10/31/2025.

Why GSK plc matters for US investors

GSK's NYSE listing (ticker: GSK) offers US investors exposure to a global pharma leader with significant revenue from the American market. Its vaccines portfolio, including those targeting US public health priorities, underscores relevance amid ongoing healthcare spending.

Conclusion

The publication of GSK plc's 2025 Annual Report provides investors with updated insights into financial performance and strategy for the year ended December 31, 2025. With a solid market position in vaccines and specialties, plus NYSE accessibility, it remains a notable name in global pharma. Market data shows stability, though investors should review full disclosures amid sector dynamics.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.